SCHEMBL221682

SCHEMBL221682

FN1CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL716246 0.84
SCHEMBL285899 0.80
SCHEMBL10614207 0.80
Azetidine SCHEMBL6112491 0.80 ALDH1A1 (0.36)
Hydrochloric Acid SCHEMBL2306666 0.77
Hydrochloric Acid SCHEMBL518222 0.77
SCHEMBL13504570 0.77
SCHEMBL11057613 0.76
SCHEMBL14523169 0.73
SCHEMBL20309204 0.73 CHKA (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240140915-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS VIVIDION THERAPEUTICS, INC. 2024-05-02 US claimed
WO-2024092185-A1 ACYL SULFONAMIDE COMPOUNDS AS INHIBITORS OF POLYOMAVIRUS VIA NOVA THERAPEUTICS, INC. (US) 2024-05-02 WO claimed
US-20240124489-A1 SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2024-04-18 US claimed
US-20240101553-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-03-28 US claimed
US-20240067612-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS VIVIDION THERAPEUTICS, INC. 2024-02-29 US claimed
CN-111295382-B Bridged bicyclic compounds as farnesyl ester X receptor modulators 百时美施贵宝公司 2024-02-02 CN claimed
WO-2024010782-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS VIVIDION THERAPEUTICS, INC. (US) 2024-01-11 WO claimed
US-11655243-B2 Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists HOFFMANN-LA ROCHE INC. (US) 2023-05-23 US claimed
US-20220289739-A1 SUBSTITUTED BENZIMIDAZOLONE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2022-09-15 US claimed
CN-114126713-A Substituted benzimidazolone compounds 百时美施贵宝公司 2022-03-01 CN claimed
CN-104837818-A Pyridine-2-amides useful as CB2 agonists HOFFMANN LA ROCHE 2015-08-12 CN claimed
CN-104768950-A Pyrazine derivatives HOFFMANN LA ROCHE 2015-07-08 CN claimed
CN-104364249-A Triazolo compounds as pde10 inhibitors BOSCH GMBH ROBERT 2015-02-18 CN claimed
CN-104271566-A Substituted dipyridylamines and uses thereof HOFFMANN LA ROCHE 2015-01-07 CN claimed
US-20140371464-A1 PROCESS FOR THE PREPARATION OF CHIRAL ISOXAZOLINE AZETIDINE DERIVATIVES AS ANTIPARASITIC AGENTS ZOETIS SERVICES LLC 2014-12-18 US claimed
EP-2809667-A1 PROCESS FOR THE PREPARATION OF CHIRAL ISOXAZOLINE AZETIDINE DERIVATIVES AS ANTIPARASITIC AGENTS Zoetis LLC (US) 2014-12-10 EP claimed
CN-104169276-A Process for the preparation of chiral isoxazoline azetidine derivatives as antiparasitic agents ZOETIS LLC 2014-11-26 CN claimed
CN-103974948-A Substituted benzyl indazoles as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases Bayer Pharma AG 2014-08-06 CN claimed
CN-102459162-B Novel cyclopentane derivatives HOFFMANN LA ROCHE 2014-01-08 CN claimed
WO-2013116236-A1 PROCESS FOR THE PREPARATION OF CHIRAL ISOXAZOLINE AZETIDINE DERIVATIVES AS ANTIPARASITIC AGENTS ZOETIS LLC (US) 2013-08-08 WO claimed